Biocon has announced that its insulin manufacturing facility in Malaysia has received an establishment inspection report from the US Food and Drug Administration, closing out an inspection conducted between 10 February and 21 February this year with ‘voluntary action indicated’ status for the plant.
The Factory Floor: Biocon Celebrates Malaysian Insulin Plant Clearance
As MedPharm And Lupin Successfully Complete FDA Inspections
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.
